A5000892631- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- COVID-19 and healthcare impacts
- Organ Donation and Transplantation
- Blood donation and transfusion practices
- Eosinophilic Disorders and Syndromes
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- COVID-19 Clinical Research Studies
University Hospital of Wales
2017-2024
Cardiff University
2022
Allogeneic stem-cell transplant allows for the delivery of curative graft-versus-leukemia (GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance T-cell chimerism, measurable residual disease (MRD) and blast HLA-DR expression may inform whether GVL effectiveness is reduced. We report here prognostic impact these biomarkers allografted AML/MDS. One hundred eighty-seven from FIGARO, a randomized trial reduced-intensity conditioning regimens AML/MDS, were alive...
Abstract COVID-19 has been associated with high mortality in patients treated Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome improved over time primary objective of assessing COVID-19-attributable Omicron period 2022 compared to previous years. Data this multicenter study were collected using MED-A and report forms developed by EBMT. One-hundred-eighty included analysis, 39 diagnosed 2020, 35 2021 106 2022. The median...
Autologous hematopoietic cell transplantation (auto-HCT) may be performed in multiple myeloma (MM) patients relapsing after a previous auto-HCT. For those without an adequate dose of stored stem cells, remobilization is necessary. This retrospective study included who, following disease relapse the first auto-HCT(s), underwent and auto-HCT using these cells. There were 305 patients, 68% male, median age at salvage was 59 years. The time to first-line penultimate auto-HCT(s) 30.6 months,...
Conditioning protocols for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) are being developed continuously to improve their anti-leukemic efficacy and reduce toxicity. In this study, we compared the conditioning protocol of fludarabine with melphalan 140 mg/m
Background: Multiple myeloma (MM) is an incurable hematologic malignancy despite recent therapeutic advances. In the context of lenalidomide-sensitive relapse, one preferred options from EHA/ESMO and IMWG recommendations combination carfilzomib-lenalidomide-dexamethasone (KRd). This regimen has been approved based on ASPIRE trial with a PFS 26.3 months vs 17.6 for Rd alone (HR = 0.69, p=0.0001). younger patients, second autologous hematopoietic cell transplantation (auto-HCT) remains option...